Reigning in costs is a key component of healthcare reform. So it is clear why it will be essential for both providers and policy makers to identify those most at risk for driving up costs.
Reigning in costs is a key component of healthcare reform. So it is clear why it will be essential for both providers and policy makers to identify those most at risk for driving up costs.
According to a recent study published in The American Journal of Managed Care (AJMC), opioid analgesic—treated chronic pain (OAT-CP) patients who showed signs of trouble cost their health plan an estimated $12,877 a year. Precursors of trouble ranged from rapid dose escalation to doctor shopping.
“More than one-third of a sample of OAT-CP patients were identified as potentially problematic opioid users according to the study definitions applied. Healthcare service utilization and expenditures were significantly greater for this group compared with the control group,” reported the study authors.
According to an official press release on the findings:
Of the patients in the study, 39% showed signs of problematic behavior, which included doctor shopping (defined as receiving fills from 5 or more prescribers in a year) and rapid dose escalation (defined as either a 50% increase in opioid dose in the first 3 months or a 100% increase in the follow-up period). Compared with the control group, this group had:
However, proper caution and monitoring can reduce risk of opioid misuse or adverse outcomes.
“[There are] a number of tools and approaches clinicians should use to safely prescribe opioids,” the study said. “These include checking prescription drug monitoring programs, which track information on controlled substance prescriptions filled in a state, taking a careful history of substance abuse and other mental health problems, conducting routine urine drug screens in concert with pain management agreements, and making use of pain medicine consultants when problems arise.”
Read the full study here.
Around the Web
AJMC: Recognizing Certain Indicators Can Prevent Opioid Misuse and Overdose [AJMC]
Study: Pain Patients Who Show Signs of Trouble Cost Health Plan an Extra $12,877 a Year [AJMC]
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More